多能性分析用于增强血液系统恶性肿瘤的BAFF-R CAR T细胞治疗
研究优化了单细胞多能性检测平台,用健康供者制备的BAFF-R CAR T细胞产品验证,并用CD19 CAR T细胞对照。发现BAFF-R与CD19 CAR T细胞在刺激性与效应性细胞因子比例上存在定性差异,CD19 CAR T细胞多能性指数总体较低。将该检测用于首例既往CD19 CAR T治疗后进展的非霍奇金淋巴瘤患者的自体BAFF-R CAR T产品,观察到强多能性指标,与输注后CAR T细胞扩增成功及持续18个月的完全缓解相关。
要点
- 优化了单细胞多能性检测平台,可同时评估细胞因子产生、增殖和细胞毒性。
- BAFF-R与CD19 CAR T细胞在刺激性与效应性细胞因子比例上存在定性差异,CD19 CAR T细胞多能性指数总体较低。
- 首例既往CD19 CAR T治疗后进展的非霍奇金淋巴瘤患者自体BAFF-R CAR T产品显示强多能性指标,与扩增成功及持续18个月完全缓解相关。
核心结论
- 优化后的单细胞多能性检测可用于评估BAFF-R CAR T细胞产品,首例患者观察到强多能性指标并与输注后扩增成功及持续18个月完全缓解相关。
- 确定BAFF-R CAR T细胞适应性在毒性和临床结局中作用的精确因素,需将该稳健检测应用于更多接受治疗患者的分析。
研究设计与样本
- 研究使用健康供者制备的BAFF-R CAR T细胞产品优化单细胞多能性平台,并用CD19 CAR T细胞验证方案。
- 将检测应用于正在进行的临床试验中首例既往CD19 CAR T治疗后进展的非霍奇金淋巴瘤患者的自体BAFF-R CAR T细胞产品。
- 该试验在www.ClinicalTrials.gov注册号为#NCT05370430。
主要发现
- BAFF-R与CD19 CAR T细胞在刺激性与效应性细胞因子比例上观察到基于靶抗原密度的定性差异,CD19 CAR T细胞多能性指数总体较低。
- 首例患者自体BAFF-R CAR T产品观察到强多能性指标,与输注后CAR T细胞扩增成功及持续18个月完全缓解相关。
局限性
- 确定BAFF-R CAR T细胞适应性在毒性和临床结局中作用的精确因素,需将该稳健检测应用于更多接受治疗患者的分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising immunotherapeutic strategy for eradicating human cancers. Their therapeutic success and durability of clinical responses hinges, in large part, on their functional capacity, including the ability of these engineered cells to simultaneously expand and persist after infusion into patients. CD19 CAR T-cell polyfunctionality, assessing the simultaneous functions of cytokine production, proliferation, and cytotoxicity has been reported to correlate with clinical outcomes. Assay optimization is potentially limited by the heterogeneous nature of CAR T-cell infusion products and target specificity. We optimized a single-cell platform for polyfunctionality using CAR T-cell products manufactured from healthy donors, engineered against a novel target, B-cell-activating factor receptor (BAFF-R) and validated the protocol using CD19 CAR T cells. We observed distinct qualitative differences between BAFF-R and CD19 CAR T cells relative to the proportions of stimulatory vs effector cytokines, based on target antigen density, and, generally, CD19 CAR T cells exhibited lower indices of polyfunctionality. Finally, we applied our assay to the autologous BAFF-R CAR T-cell product generated from the first patient with non-Hodgkin lymphoma treated in an ongoing clinical trial who had progressed after prior CD19 CAR T-cell therapy. We observed robust indicators of polyfunctionality, which correlated with successful CAR T-cell expansion after infusion and achievement of durable complete remission ongoing after 18 months. The precise identification of factors determining the role of BAFF-R CAR T-cell fitness in toxicity and clinical outcome will require the application of this robust assay in the analysis of additional treated patients. This trial was registered at www.ClinicalTrials.gov as #NCT05370430.
引用
- Dong Z, Budde LE, Oh E, et al. Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies. Blood Adv. 2024. PMID: 38885481. doi:10.1182/bloodadvances.2024013195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。